News
Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology comes to RNA ...
The FDA has approved Johnson & Johnson’s IL-23 blocker Tremfya to treat ulcerative colitis, a boost to the pharma’s hopes that the drug will serve as a worthy follow-up to ...
GSK is handing mRNA vaccine partner CureVac €400 million ($429 million) upfront to take over full rights to the influenza and Covid vaccine candidates they have been collaborating on, while ...
To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Teladoc Health's CEO Jason Gorevic is stepping down ...
Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...
Reps. Kelly Armstrong (R-ND) and Ben Cline (R-VA) sent a letter last week to Attorney General Merrick Garland, asking why the Department of Justice is willing to incur potential patent ...
Merck has struck a deal to buy Harpoon Therapeutics for $680 million, beefing up its oncology pipeline with a portfolio of T cell engagers. At $23 per share, Merck’s offer ...
As Eli Lilly launches its newly approved weight loss med Zepbound to much fanfare, Novo Nordisk is tossing a next-gen candidate in the ring. The Danish pharma company is launching ...
CARGO Therapeutics will join the Nasdaq on Friday morning in what some industry insiders think could be the final, maybe penultimate, initial public offering for a biotech this year. ...
Gene therapy startup enGene became a public biotech on Wednesday after completing its combination with Forbion European Acquisition, a blank check company formed in 2021. The Montreal and ...
After years of being a rumored biotech buyout target, Mirati was ultimately acquired by Bristol Myers Squibb earlier this month for $4.8 billion. But the pharma buyer once offered more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback